Binding of vitamin E in mammalian tumor cells in culture

Abstract

Radioactive vitamin E (D-α-[5-methyl-3H]tocopherol) bound with the cytosol (100,000g supernatant), pellet (100,000g pellet), crude nuclear, and purified chromatin fractions from mouse neuroblastoma (NBP2) and rat glioma (C-6) cells in culture.

The level and type of vitamin E binding proteins in the cytosol depended upon the cell type.

When the cytosol proteins containing radioactive vitamin E were separated by gel filtration (Sepharose 4B gel), there were five protein peaks in neuroblastoma, three peaks in glioma, and one peak in mouse B-16 melanoma cells which contained bound radioactivity.

The level of binding in the neuroblastoma cells was higher than that in glioma cells or melanoma cells.

Vitamin E remained bound to the proteins from the cytosols of neuroblastoma and glioma even after denaturation and separation by electrophoresis.

This suggests that vitamin E is tightly bound with the cytosol proteins.

There was only one vitamin E binding protein in the pellet and nuclear fractions of NB, glioma, and melanoma cells. The significance of vitamin E binding proteins in the mechanism of the effect of vitamin E on mammalian cells in culture is unknown.

 

 

About this publication.

 

See also:

- Solution of retinoids in vitamin E in the Di Bella Method biological multitherapy;

- All-Trans-Retinoic Acid (ATRA - analogues and/or derivatives);

- Neuroblastoma: Complete objective response to biological treatment;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in advanced non-small-cell lung cancer patients with low performance status;

- Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status;

- Observations on the Report of a case of pulmonary adenocarcinoma with lymph node, hepatic and osseus metastasis;

- Recurrent Glioblastoma Multiforme (grade IV – WHO 2007): a case of complete objective response achieved by means of the concomitant administration of Somatostatin and Octreotide – Retinoids – Vitamin E – Vitamin D3 – Vitamin C – Melatonin – D2 R agonists (Di Bella Method – DBM) associated with Temozolomide;

- Evaluation of the safety and efficacy of the first-line treatment with somatostatin combined with melatonisn, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report;

- The Di Bella Method (DBM) improved survival, objective response and performance status in a retrospective observational clinical study on 122 cases of breast cancer;

- Complete objective response to biological therapy of plurifocal breast carcinoma.